文献速递类风湿关节炎

滑膜组织特征列线图预测初治类风湿关节炎治疗反应

Inclusion of Synovial Tissue-Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatment-Naive Rheumatoid Arthritis Patients.
PubMed 文献 · Arthritis Rheumatol · 2021-08-09

本研究在常规诊疗中对1015例患者行超声引导下滑膜活检并计算滑膜炎评分(KSS),发现初治RA患者基线KSS与DAS28及自身抗体阳性相关;将短病程、非高疾病活动度和KSS<5整合入列线图,预测6个月DAS28缓解概率最高达81.7%。

要点

  • 初治RA患者基线KSS与DAS28直接相关,且与自身抗体阳性相关。
  • 达到6个月DAS28缓解者基线KSS更低、症状持续时间更短、疾病活动度更低。
  • 整合短病程、非高疾病活动度和KSS<5的列线图预测6个月缓解概率最高达81.7%。

核心结论

  • KSS是超声引导下滑膜活检评估滑膜炎的可靠工具,其水平取决于疾病分期和自身免疫特征。
  • 将基线临床与组织学特征整合的列线图可用于初治RA患者治疗反应的预测。

研究设计与样本

  • 研究纳入1015例各种自身免疫病患者(SYNGem队列),包括545例RA、167例PsA、199例UPIA、18例晶体诱导关节炎、26例结缔组织病和60例OA。
  • 所有患者基线接受超声引导下滑膜组织活检,按疾病分期分层,并将KSS与疾病特征和临床结局整合入列线图。
  • 在采用达标治疗策略的患者中,缓解定义为治疗开始后6个月时DAS28的变化。

主要发现

  • RA、PsA和UPIA患者的KSS与OA患者相比存在显著差异。
  • 在RA中,KSS与DAS28直接相关,并与初治RA患者的自身抗体阳性相关。
  • 基线时达到6个月DAS28缓解的初治RA患者较未缓解者KSS更低、症状持续时间更短(非常早期RA[VERA])且疾病活动度更低。
  • 逻辑回归分析确定以下6个月DAS28缓解的协同预测因素:短病程(VERA)、非高疾病活动度、基线KSS<5。
  • 整合这些基线临床和组织学特征的列线图在初治RA患者中预测6个月DAS28缓解概率最高达81.7%。

关键数值与推荐

  • 缓解定义:达标治疗策略下,治疗开始后6个月时DAS28的变化。
  • 6个月DAS28缓解的协同预测因素:短病程(VERA)、非高疾病活动度、基线KSS<5。
  • 列线图预测6个月DAS28缓解概率最高达81.7%。

临床怎么用

  • 对初治RA患者可考虑超声引导下滑膜活检获取KSS,结合短病程和非高疾病活动度,用列线图预测6个月DAS28缓解概率。
  • KSS评估滑膜炎需考虑疾病分期和自身免疫特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study applied a synovitis score obtained during routine care from ultrasound (US)-guided biopsies of synovial tissue (ST) in patients with rheumatoid arthritis (RA) and patients with other inflammatory and noninflammatory joint diseases to identify pretreatment synovial biomarkers associated with disease characteristics, and to integrate the findings into a multiparameter nomogram for use in baseline prediction of diagnosis and treatment response in treatment-naive rheumatoid arthritis (RA) patients. METHODS: The study enrolled a total of 1,015 patients with various autoimmune diseases (545 patients with RA, 167 patients with psoriatic arthritis [PsA], 199 patients with undifferentiated peripheral inflammatory arthritis [UPIA], 18 patients with crystal-induced arthritis, 26 patients with connective tissue diseases, and 60 patients with osteoarthritis [OA] [as part of the SYNGem cohort]). All patients underwent a US-guided ST biopsy at baseline, and patients were then stratified according to disease phase. The KSS, along with disease characteristics and clinical outcomes, were incorporated into a nomogram for prediction of achievement of clinical remission in RA patients who were previously naive to treatment. In patients in whom a treat-to-target strategy was applied, remission was defined as change in the Disease Activity Score in 28 joints (DAS28) at 6 months after treatment initiation. RESULTS: The KSS significantly differed among RA patients, as well as PsA patients and UPIA patients, when compared to OA patients. In RA, the KSS directly correlated with the DAS28 and was related to autoantibody positivity in treatment-naive RA patients. Moreover, at baseline, treatment-naive RA patients achieving 6-month remission according to DAS28 had a lower KSS, shorter duration of symptoms (very early RA [VERA]), and lower disease activity than treatment-naive RA patients not achieving remission according to DAS28. Results of logistic regression analysis identified the following synergistic predictive factors of achievement of DAS28-based disease remission at 6 months: having a short disease duration (VERA), not having high disease activity, and having a KSS of <5 at baseline. A nomogram integrating these baseline clinical and histologic characteristics in treatment-naive RA patients yielded an up to 81.7% probability of achieving 6-month remission according to the DAS28. CONCLUSION: The KSS is a reliable tool for synovitis assessment on US-guided ST biopsy, contingent on the phase of the disease and the autoimmune profile of each patient. This tool could be integrated within a therapeutic response-predictive nomogram for the prediction of treatment response in RA patients who were previously naive to treatment.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Alivernini S, Tolusso B, Gessi M, et al. Inclusion of Synovial Tissue-Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatment-Naive Rheumatoid Arthritis Patients. Arthritis Rheumatol. 2021. PMID: 33750008. doi:10.1002/art.41726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。